Marios E. Froudarakis, Athanasia Pataka, Periklis Pappas, Stavros Anevlavis, Evangelia Argiana, Martha Nikolaidou, George Kouliatis, Sofia Pozova, Marios Marselos and Demosthenes Bouros Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma Cancer 113
Article first published online: 29 SEP 2008 | DOI: 10.1002/cncr.23921
Lung cancer remains the most common fatal malignancy. Despite more aggressive therapies, to date only a slight improvement in survival has been obtained. Lipoplatin is a new liposomal cisplatin that already has been tested in solid tumors, with encouraging results. The purpose of the current study was to determine the maximum tolerated dose and dose-limiting toxicity of a 21‒day regimen of lipoplatin plus a fixed dose of gemcitabine in patients with refractory or resistant nonsmall cell lung carcinoma.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field